Linda Bao

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

Daniel P. Sutherlin, Linda Bao, Megan Berry et al. · Journal of Medicinal Chemistry · 2011 · 212 citations · Full text

Translational Pharmacology, Pre-clinical Pharmacology, Molecular Pharmacology +20

Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349

Zhonghua Pei, Elizabeth Blackwood, Lichuan Liu et al. · ACS Medicinal Chemistry Letters · 2012 · 46 citations · Full text

Drug Target, Chemoprevention Strategy, Advanced Lead 1 +21

In Vitro and In Vivo Evaluation of Amorphous Solid Dispersions Generated by Different Bench-Scale Processes, Using Griseofulvin as a Model Compound

Po‐Chang Chiang, Yong Cui, Yingqing Ran et al. · The AAPS Journal · 2013 · 32 citations · Full text

Materials Science, Engineering, Excipients +7

Discovery of TRPA1 Antagonist <b>GDC-6599</b>: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory Disease

Jack A. Terrett, Justin Q. Ly, Paula Katavolos et al. · Journal of Medicinal Chemistry · 2024 · 19 citations · Full text

On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: from Imaging to Therapy

Pragya Adhikari, Guangmin Li, MaryAnn Go et al. · Journal of the American Chemical Society · 2024 · 15 citations